Drug Profile
Liatermin - MedGenesis Therapeutix
Alternative Names: BVF-014; GDNF; Glial-derived neutrotrophic factor; r-metHuGDNFLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; MedGenesis Therapeutix
- Class Antiparkinsonians; Biological proteins; Nerve growth factors; Neuroprotectants
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inborn genetic disorders; Parkinson's disease; Peripheral nerve injuries
- Discontinued Amyotrophic lateral sclerosis; Deafness; Epilepsy; Pain; Sensorineural hearing loss
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Inborn genetic disorders in Canada (Parenteral)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Peripheral-nerve-injuries in Canada (Parenteral)
- 17 Feb 2021 No development reported - Phase-II for Parkinson's disease in United Kingdom (Intracerebral)